DaVita reported revenue of $3.578 billion for the third quarter of 2026
DaVita Inc. released results for the third quarter of 2026: revenue was $3.578 billion, and operating income was $499 million. The data reflect the company's financial position for the reporting period ended September 30, 2026.
Key points
- Company revenue in the third quarter of 2026 reached $3.578 billion, up 4.6% from the same period last year.
- The company recognized a $62 million impairment charge for goodwill and other assets in China, which impacted operating income.
Key quarterly metrics
Company revenue in the third quarter of 2026 reached $3.578 billion, up 4.6% from the same period last year. Operating income was $499 million, a decline of 1.3% compared to last year. Earnings per share (EPS) was $3.40, higher than the $2.04 reported a year earlier.
During the third quarter, the company repurchased 0.6 million shares for $111 million. After the quarter ended, between September 30 and October 27, 2026, it repurchased another 0.5 million shares for $87 million.
Quarter vs the same quarter a year earlier
Revenue by quarter, $B
Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.
Risks and uncertainties
The company recognized a $62 million impairment charge for goodwill and other assets in China, which impacted operating income. Additionally, Berkshire Hathaway and Warren Buffett sold 382,563 company shares on October 27, 2026.
The business remains vulnerable to shortages of skilled medical personnel and potential issues related to the 2025 cyber incident, which could cause disruptions to billing systems.
What to watch
The published financial data is unaudited and may change before the company files its report for the third quarter of 2026. Investors should track this document in the SEC EDGAR system for final reporting.
Original sources
- DaVita Inc. 3rd Quarter 2026 Results
- 8-K EX-99.1 filing, October 29, 2026
- financial data (XBRL)
- 10-Q filing, October 29, 2026
- 4 filing, October 29, 2026
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Davita
A notification in your browser or on your phone when we publish about Davita. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
